|Bid||36.53 x 1100|
|Ask||37.10 x 2900|
|Day's range||36.53 - 38.00|
|52-week range||33.62 - 47.24|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||13.94|
|Forward dividend & yield||2.96 (8.05%)|
|Ex-dividend date||29 Sept 2022|
|1y target est||N/A|
NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”), announced today that it has entered into a research collaboration with Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Janssen will
Due to high demand from fans in both the art and racing worlds, the original artwork that inspired McLaren Racing's 2021 livery for the final race in Abu Dhabi is being auctioned in digital form with proceeds going to charity.
An emerging artist has had her work spotlighted for the world to see, featured on one of the fastest-moving canvases on earth.